Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma

Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patients and to investigate the exposure–response relatio...

Full description

Bibliographic Details
Main Authors: David Balakirouchenane, Sarah Guégan, Chantal Csajka, Anne Jouinot, Valentine Heidelberger, Alicja Puszkiel, Ouidad Zehou, Nihel Khoudour, Perrine Courlet, Nora Kramkimel, Coralie Lheure, Nathalie Franck, Olivier Huillard, Jennifer Arrondeau, Michel Vidal, Francois Goldwasser, Eve Maubec, Nicolas Dupin, Selim Aractingi, Monia Guidi, Benoit Blanchet
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
melanoma
BRAF
dabrafenib
hydroxy-dabrafenib
trametinib
population pharmacokinetics
Online Access:https://www.mdpi.com/2072-6694/12/4/931

Internet

https://www.mdpi.com/2072-6694/12/4/931

Similar Items